Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we r...
Saved in:
Published in | Hepatology communications Vol. 3; no. 8; pp. 1085 - 1097 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
01.08.2019
John Wiley and Sons Inc Wolters Kluwer Health/LWW |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we report efficacy of the novel nonbile acid FXR agonist tropifexor (LJN452) in two distinct preclinical models of NASH. The efficacy of tropifexor at <1 mg/kg doses was superior to that of OCA at 25 mg/kg in the liver in both NASH models. In a chemical and dietary model of NASH (Stelic animal model [STAM]), tropifexor reversed established fibrosis and reduced the nonalcoholic fatty liver disease activity score and hepatic triglycerides. In an insulin‐resistant obese NASH model (amylin liver NASH model [AMLN]), tropifexor markedly reduced steatohepatitis, fibrosis, and profibrogenic gene expression. Transcriptome analysis of livers from AMLN mice revealed 461 differentially expressed genes following tropifexor treatment that included a combination of signatures associated with reduction of oxidative stress, fibrogenesis, and inflammation. Conclusion: Based on preclinical validation in animal models, tropifexor is a promising investigational therapy that is currently under phase 2 development for NASH. |
---|---|
AbstractList | Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we report efficacy of the novel nonbile acid FXR agonist tropifexor (LJN452) in two distinct preclinical models of NASH. The efficacy of tropifexor at <1 mg/kg doses was superior to that of OCA at 25 mg/kg in the liver in both NASH models. In a chemical and dietary model of NASH (Stelic animal model [STAM]), tropifexor reversed established fibrosis and reduced the nonalcoholic fatty liver disease activity score and hepatic triglycerides. In an insulin‐resistant obese NASH model (amylin liver NASH model [AMLN]), tropifexor markedly reduced steatohepatitis, fibrosis, and profibrogenic gene expression. Transcriptome analysis of livers from AMLN mice revealed 461 differentially expressed genes following tropifexor treatment that included a combination of signatures associated with reduction of oxidative stress, fibrogenesis, and inflammation.
Conclusion
: Based on preclinical validation in animal models, tropifexor is a promising investigational therapy that is currently under phase 2 development for NASH. Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we report efficacy of the novel nonbile acid FXR agonist tropifexor (LJN452) in two distinct preclinical models of NASH. The efficacy of tropifexor at <1 mg/kg doses was superior to that of OCA at 25 mg/kg in the liver in both NASH models. In a chemical and dietary model of NASH (Stelic animal model [STAM]), tropifexor reversed established fibrosis and reduced the nonalcoholic fatty liver disease activity score and hepatic triglycerides. In an insulin‐resistant obese NASH model (amylin liver NASH model [AMLN]), tropifexor markedly reduced steatohepatitis, fibrosis, and profibrogenic gene expression. Transcriptome analysis of livers from AMLN mice revealed 461 differentially expressed genes following tropifexor treatment that included a combination of signatures associated with reduction of oxidative stress, fibrogenesis, and inflammation. Conclusion: Based on preclinical validation in animal models, tropifexor is a promising investigational therapy that is currently under phase 2 development for NASH. Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid-derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we report efficacy of the novel nonbile acid FXR agonist tropifexor (LJN452) in two distinct preclinical models of NASH. The efficacy of tropifexor at <1 mg/kg doses was superior to that of OCA at 25 mg/kg in the liver in both NASH models. In a chemical and dietary model of NASH (Stelic animal model [STAM]), tropifexor reversed established fibrosis and reduced the nonalcoholic fatty liver disease activity score and hepatic triglycerides. In an insulin-resistant obese NASH model (amylin liver NASH model [AMLN]), tropifexor markedly reduced steatohepatitis, fibrosis, and profibrogenic gene expression. Transcriptome analysis of livers from AMLN mice revealed 461 differentially expressed genes following tropifexor treatment that included a combination of signatures associated with reduction of oxidative stress, fibrogenesis, and inflammation. : Based on preclinical validation in animal models, tropifexor is a promising investigational therapy that is currently under phase 2 development for NASH. |
Author | Walker, John Hernandez, Eloy D. Chianelli, Donatella Dubois, Claire Kim, Young Chen, Lihao Federe, Glenn C. Liu, Bo Joseph, Sean B. Meeusen, Shelly Bao, Dingjiu Zoll, Jocelyn Badman, Michael K. Rucker, Paul V. Klickstein, Lloyd B. Laffitte, Bryan Fang, Bin Schmeits, James McNamara, Peter Zheng, Lianxing Xu, Jie Valdez, Reginald A. Molteni, Valentina Tully, David C. Dietrich, William F. |
AuthorAffiliation | 1 Genomics Institute of the Novartis Research Foundation La Jolla CA 2 Novartis Institutes for BioMedical Research Cambridge MA 3 Comparative Biology and Safety Sciences Amgen, Inc. Cambridge MA 6 Novartis Institutes for BioMedical Research Emeryville CA 5 California Institute for Biomedical Research La Jolla CA 4 Inception Sciences, Inc. San Diego CA |
AuthorAffiliation_xml | – name: 4 Inception Sciences, Inc. San Diego CA – name: 6 Novartis Institutes for BioMedical Research Emeryville CA – name: 1 Genomics Institute of the Novartis Research Foundation La Jolla CA – name: 3 Comparative Biology and Safety Sciences Amgen, Inc. Cambridge MA – name: 5 California Institute for Biomedical Research La Jolla CA – name: 2 Novartis Institutes for BioMedical Research Cambridge MA |
Author_xml | – sequence: 1 givenname: Eloy D. surname: Hernandez fullname: Hernandez, Eloy D. organization: Genomics Institute of the Novartis Research Foundation – sequence: 2 givenname: Lianxing surname: Zheng fullname: Zheng, Lianxing organization: Novartis Institutes for BioMedical Research – sequence: 3 givenname: Young surname: Kim fullname: Kim, Young organization: Genomics Institute of the Novartis Research Foundation – sequence: 4 givenname: Bin surname: Fang fullname: Fang, Bin organization: Genomics Institute of the Novartis Research Foundation – sequence: 5 givenname: Bo surname: Liu fullname: Liu, Bo organization: Genomics Institute of the Novartis Research Foundation – sequence: 6 givenname: Reginald A. surname: Valdez fullname: Valdez, Reginald A. organization: Amgen, Inc – sequence: 7 givenname: William F. surname: Dietrich fullname: Dietrich, William F. organization: Novartis Institutes for BioMedical Research – sequence: 8 givenname: Paul V. surname: Rucker fullname: Rucker, Paul V. organization: Genomics Institute of the Novartis Research Foundation – sequence: 9 givenname: Donatella surname: Chianelli fullname: Chianelli, Donatella organization: Genomics Institute of the Novartis Research Foundation – sequence: 10 givenname: James surname: Schmeits fullname: Schmeits, James organization: Genomics Institute of the Novartis Research Foundation – sequence: 11 givenname: Dingjiu surname: Bao fullname: Bao, Dingjiu organization: Genomics Institute of the Novartis Research Foundation – sequence: 12 givenname: Jocelyn surname: Zoll fullname: Zoll, Jocelyn organization: Genomics Institute of the Novartis Research Foundation – sequence: 13 givenname: Claire surname: Dubois fullname: Dubois, Claire organization: Inception Sciences, Inc – sequence: 14 givenname: Glenn C. surname: Federe fullname: Federe, Glenn C. organization: Genomics Institute of the Novartis Research Foundation – sequence: 15 givenname: Lihao surname: Chen fullname: Chen, Lihao organization: Novartis Institutes for BioMedical Research – sequence: 16 givenname: Sean B. surname: Joseph fullname: Joseph, Sean B. organization: California Institute for Biomedical Research – sequence: 17 givenname: Lloyd B. surname: Klickstein fullname: Klickstein, Lloyd B. organization: Novartis Institutes for BioMedical Research – sequence: 18 givenname: John surname: Walker fullname: Walker, John organization: Genomics Institute of the Novartis Research Foundation – sequence: 19 givenname: Valentina surname: Molteni fullname: Molteni, Valentina organization: Genomics Institute of the Novartis Research Foundation – sequence: 20 givenname: Peter surname: McNamara fullname: McNamara, Peter organization: Genomics Institute of the Novartis Research Foundation – sequence: 21 givenname: Shelly surname: Meeusen fullname: Meeusen, Shelly organization: Genomics Institute of the Novartis Research Foundation – sequence: 22 givenname: David C. surname: Tully fullname: Tully, David C. organization: Novartis Institutes for BioMedical Research – sequence: 23 givenname: Michael K. surname: Badman fullname: Badman, Michael K. organization: Novartis Institutes for BioMedical Research – sequence: 24 givenname: Jie surname: Xu fullname: Xu, Jie email: jxu@gnf.org organization: Genomics Institute of the Novartis Research Foundation – sequence: 25 givenname: Bryan surname: Laffitte fullname: Laffitte, Bryan organization: Inception Sciences, Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31388629$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1uEzEQgC1UREvogRdAlrjAIa1_dtf2BSmq0jZSERUUwc3yemcTRxs72JuS3jhy5Bl5ErxNqVokLmt79pvPY3ueoz0fPCD0kpIjSgg7XsC6OKK8kk_QASsEHbOy-Lr3YL6PDlNaEkKoYpQq8gztc8qlrJg6QD-vYli7FrYh_v7x6z00zvTQ4Ekdw9z0LngcWvypB9OHvFGO9C5h4xt86jKS8mKW8CSlYHeJX1y_wP0C8MTn7K1rcso14DPwgKfbdYSUBullDK3rADuPP4YGfJ9eoKet6RIc3o0j9Pl0enVyPr74cDY7mVyMbcmFHFMq8hEaRipoDC1FLaocaCzjylREsVrKPBWCGFJJQY0SzLLaFm1d1q1VnI_QbOdtglnqdXQrE290ME7fBkKcaxN7ZzvQraIEKCkMo7KghZGs5pwz0tq2KGSpsuvdzrXe1CtobD5HNN0j6eM_3i30PFzrqhK5SpIFb-4EMXzbQOr1yiULXWc8hE3SjFWKK15KmdHX_6DLsIk-X9VACV6q4TtCb3eUzY-TIrT3xVCih3bRQ7vooV0y--ph9ffk3-bIwPEO-J6f6ub_Jn0-vSxulX8AAh3MtQ |
CitedBy_id | crossref_primary_10_1016_j_ejmech_2023_115614 crossref_primary_10_1111_liv_14906 crossref_primary_10_3390_ijms241612748 crossref_primary_10_1080_03602532_2022_2097253 crossref_primary_10_1038_s41574_021_00507_z crossref_primary_10_1002_cpdd_1208 crossref_primary_10_1186_s13765_022_00755_1 crossref_primary_10_1016_j_jcmgh_2023_08_004 crossref_primary_10_1016_j_molmed_2021_10_005 crossref_primary_10_3389_fmed_2020_00544 crossref_primary_10_1002_hep4_1443 crossref_primary_10_3389_fphar_2020_01247 crossref_primary_10_1021_acs_jmedchem_9b01621 crossref_primary_10_1016_j_bcp_2023_115776 crossref_primary_10_3390_ijms23147841 crossref_primary_10_1097_HC9_0000000000000127 crossref_primary_10_1590_acb360902 crossref_primary_10_3390_diseases8020020 crossref_primary_10_1016_j_jhep_2022_06_018 crossref_primary_10_1155_2022_2823214 crossref_primary_10_1038_s41401_022_00880_z crossref_primary_10_1016_j_biopha_2023_115345 crossref_primary_10_1080_17474124_2020_1797485 crossref_primary_10_1124_dmd_120_000349 crossref_primary_10_14336_AD_2023_0830 crossref_primary_10_1007_s00535_020_01681_z crossref_primary_10_1055_s_0041_1731707 crossref_primary_10_1080_14728214_2020_1796968 crossref_primary_10_1016_j_metabol_2021_154844 crossref_primary_10_1038_s41392_024_01811_6 crossref_primary_10_1111_febs_15877 crossref_primary_10_1016_j_bcp_2023_115900 crossref_primary_10_1016_j_metabol_2020_154144 crossref_primary_10_1097_MPG_0000000000003135 crossref_primary_10_1038_s41591_022_02200_8 crossref_primary_10_3748_wjg_v26_i39_5919 crossref_primary_10_3389_fcell_2022_1089124 crossref_primary_10_1007_s12072_019_10001_4 crossref_primary_10_1021_acs_jmedchem_0c01065 crossref_primary_10_1016_j_jhep_2021_01_047 crossref_primary_10_14218_JCTH_2020_00040 crossref_primary_10_1016_j_jhep_2023_07_034 crossref_primary_10_1016_j_lfs_2023_121614 crossref_primary_10_3390_nu14234950 crossref_primary_10_1186_s12876_020_01356_2 crossref_primary_10_1016_j_mce_2022_111678 crossref_primary_10_1042_BSR20212791 crossref_primary_10_3390_ijms23041986 crossref_primary_10_1038_s41392_022_01070_3 crossref_primary_10_1080_14656566_2020_1774553 crossref_primary_10_1093_lifemeta_load032 crossref_primary_10_1002_cpdd_1140 crossref_primary_10_7554_eLife_91438 crossref_primary_10_1016_j_jhepr_2022_100544 crossref_primary_10_3389_fphar_2022_973366 crossref_primary_10_2139_ssrn_4189786 crossref_primary_10_1002_cpdd_762 crossref_primary_10_1136_bmj_m4747 crossref_primary_10_1016_j_bioorg_2023_107071 crossref_primary_10_1016_j_bmcl_2022_128993 crossref_primary_10_7554_eLife_91438_3 crossref_primary_10_1016_j_metabol_2020_154203 crossref_primary_10_1016_j_livres_2021_02_002 crossref_primary_10_3390_livers1030014 crossref_primary_10_20538_1682_0363_2022_3_154_165 crossref_primary_10_1016_j_medj_2021_03_002 crossref_primary_10_1097_HEP_0000000000000439 |
Cites_doi | 10.1152/ajpgi.00079.2013 10.1016/j.cgh.2014.04.014 10.1007/s10620-017-4684-x 10.1194/jlr.M034876 10.3748/wjg.v22.i41.9039 10.1038/nrd.2015.3 10.1016/j.jhep.2009.03.025 10.1038/nrgastro.2013.171 10.1016/j.mce.2012.05.004 10.1002/hep.24268 10.1038/srep33453 10.1152/ajpgi.00476.2011 10.1016/S0140-6736(13)62152-2 10.1194/jlr.M001602 10.1038/nrm3312 10.3748/wjg.v24.i2.179 10.1016/j.cell.2018.09.053 10.1016/j.tips.2009.08.001 10.1126/science.284.5418.1365 10.1016/S1097-2765(00)00051-4 10.1016/S0140-6736(14)61933-4 10.1053/j.gastro.2004.08.001 10.1172/JCI37385 10.1016/j.cmet.2005.09.001 10.1002/hep.22519 10.1016/j.jhep.2017.10.031 10.1007/s12072-010-9202-6 10.1126/science.284.5418.1362 10.1053/j.gastro.2014.11.039 10.1021/jm070633p 10.1172/JCI21025 10.1124/mol.110.064501 10.1038/nrgastro.2013.151 10.1016/j.molmet.2017.09.001 10.1080/17460441.2018.1410135 10.1016/S0168-8278(17)31230-8 10.1053/j.gastro.2013.05.042 10.1016/0092-8674(95)90530-8 10.1038/srep17288 10.1016/S0021-9258(18)64849-5 10.1038/nprot.2012.016 10.1124/mol.105.012104 10.1172/JCI67804 10.1073/pnas.0506982103 10.1210/me.2007-0527 10.1002/hep.29367 10.1021/acs.jmedchem.7b00907 10.1021/jm025529g 10.1002/hep.20701 |
ContentType | Journal Article |
Copyright | 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. 2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. – notice: 2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1002/hep4.1368 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Open Access PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Open Access: Wiley-Blackwell Open Access Journals url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Hepatology Communications |
EISSN | 2471-254X |
EndPage | 1097 |
ExternalDocumentID | oai_doaj_org_article_f910e104a218414a82b33320fcf44859 10_1002_hep4_1368 31388629 HEP41368 |
Genre | article Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GrantInformation_xml | – fundername: Genomics Institute of Novartis Research Foundation |
GroupedDBID | 0R~ 1OC 24P 53G 7X7 8FI 8FJ AAAAV AAHHS AAIQE ABUWG ACCFJ ACILI ACXJB ACXQS ADBBV ADGGA ADHPY ADKYN ADPDF ADZMN ADZOD AECAP AEEZP AEQDE AFKRA AFUWQ AHQNM AIWBW AJAOE AJBDE AJNWD AJZMW ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMNEI AOHHW AOIJS AVUZU BCNDV BENPR BPHCQ BVXVI CCPQU DIWNM EBS EEVPB EJD FCALG FYUFA GQDEL GROUPED_DOAJ HMCUK HYE IAO IHR INH M~E OK1 OVD OVDNE PIMPY PQQKQ PROAC RPM TEORI TSPGW UKHRP WIN ITC NPM AAHPQ AAYXX AFDTB CITATION IKREB 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c5378-117190d206eda157b76719dc239a6092b88239770a06871a972c2bc4fb5bfc933 |
IEDL.DBID | RPM |
ISSN | 2471-254X |
IngestDate | Tue Oct 22 15:07:55 EDT 2024 Tue Sep 17 21:25:09 EDT 2024 Wed Dec 04 13:54:52 EST 2024 Tue Nov 19 07:11:56 EST 2024 Fri Dec 06 03:03:04 EST 2024 Sat Sep 28 08:35:15 EDT 2024 Sat Aug 24 01:11:16 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | Attribution-NonCommercial-NoDerivs http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5378-117190d206eda157b76719dc239a6092b88239770a06871a972c2bc4fb5bfc933 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Potential conflict of interest: Dr. Zheng, Dr. Fang, Dr. Dietrich, Dr. Bao, Dr. Klickstein, Dr. Molteni, Dr. McNamara, Dr. Tully, Dr. Badman, and Dr. Xu own stock in and are employed by Novartis; Dr. Hernandez, Dr. Kim, Dr. Rucker, Dr. Chianelli, Dr. Schmeits, Dr. Zoll, Dr. Federe, Dr. Chen, Dr. Walker and Dr. Meeusen are employed by Novartis; Dr. Liu and Dr. Laffitte owns stock in Novartis; the other authors have nothing to report. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672390/ |
PMID | 31388629 |
PQID | 2267359267 |
PQPubID | 4370311 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f910e104a218414a82b33320fcf44859 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6672390 proquest_miscellaneous_2269393588 proquest_journals_2267359267 crossref_primary_10_1002_hep4_1368 pubmed_primary_31388629 wiley_primary_10_1002_hep4_1368_HEP41368 |
PublicationCentury | 2000 |
PublicationDate | August 2019 |
PublicationDateYYYYMMDD | 2019-08-01 |
PublicationDate_xml | – month: 08 year: 2019 text: August 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York – name: Hoboken |
PublicationTitle | Hepatology communications |
PublicationTitleAlternate | Hepatol Commun |
PublicationYear | 2019 |
Publisher | Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins John Wiley and Sons Inc Wolters Kluwer Health/LWW |
Publisher_xml | – name: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins – name: John Wiley and Sons Inc – name: Wolters Kluwer Health/LWW |
References | 2017; 6 2004; 127 2015; 148 2000; 6 1957; 226 2013; 368 2015; 385 2011; 53 2013; 123 1999; 284 2012; 13 2009; 119 2005; 68 2018; 175 2009; 51 2013; 10 2013; 54 2002; 45 2008; 22 2010; 4 2014; 11 2017; 62 2010; 78 2015; 13 2015; 5 2017; 60 2017; 66 2013; 305 2013; 145 2005; 41 2013; 382 2007; 50 2018; 67 2012; 302 2016; 15 2018; 68 2018; 24 2016; 6 2009; 30 1995; 81 2004; 113 2008; 48 2016; 64 2005; 2 2012; 7 2010; 51 2006; 103 2016; 22 2018; 13 (hep41368-bib-0028-20240114) 2015; 385 (hep41368-bib-0029-20240114) 2007; 50 (hep41368-bib-0037-20240114) 2017; 6 (hep41368-bib-0036-20240114) 2013; 305 (hep41368-bib-0006-20240114) 2017; 62 (hep41368-bib-0016-20240114) 2002; 45 (hep41368-bib-0049-20240114) 2013; 123 (hep41368-bib-0031-20240114) 2017; 60 (hep41368-bib-0039-20240114) 2016; 22 (hep41368-bib-0014-20240114) 2005; 2 (hep41368-bib-0017-20240114) 2010; 4 (hep41368-bib-0022-20240114) 2004; 127 (hep41368-bib-0026-20240114) 2010; 51 (hep41368-bib-0007-20240114) 2013; 382 (hep41368-bib-0005-20240114) 2015; 148 (hep41368-bib-0011-20240114) 1999; 284 (hep41368-bib-0033-20240114) 1957; 226 (hep41368-bib-0043-20240114) 2009; 119 (hep41368-bib-0012-20240114) 1999; 284 (hep41368-bib-0044-20240114) 2017; 66 (hep41368-bib-0019-20240114) 2008; 22 (hep41368-bib-0015-20240114) 2014; 11 (hep41368-bib-0041-20240114) 2018; 13 (hep41368-bib-0048-20240114) 2009; 30 (hep41368-bib-0001-20240114) 2016; 15 (hep41368-bib-0035-20240114) 2012; 7 (hep41368-bib-0040-20240114) 2016; 64 (hep41368-bib-0047-20240114) 2018; 175 (hep41368-bib-0003-20240114) 2018; 67 (hep41368-bib-0020-20240114) 2009; 51 (hep41368-bib-0034-20240114) 2012; 302 (hep41368-bib-0027-20240114) 2013; 145 (hep41368-bib-0004-20240114) 2011; 53 (hep41368-bib-0024-20240114) 2015; 5 (hep41368-bib-0030-20240114) 2010; 78 (hep41368-bib-0023-20240114) 2004; 113 (hep41368-bib-0010-20240114) 1995; 81 (hep41368-bib-0042-20240114) 2018; 68 (hep41368-bib-0009-20240114) 2013; 368 (hep41368-bib-0038-20240114) 2013; 54 (hep41368-bib-0045-20240114) 2018; 24 (hep41368-bib-0008-20240114) 2012; 13 (hep41368-bib-0013-20240114) 2000; 6 (hep41368-bib-0046-20240114) 2015; 13 (hep41368-bib-0025-20240114) 2006; 103 (hep41368-bib-0002-20240114) 2013; 10 (hep41368-bib-0021-20240114) 2016; 6 (hep41368-bib-0050-20240114) 2005; 68 (hep41368-bib-0018-20240114) 2008; 48 (hep41368-bib-0032-20240114) 2005; 41 |
References_xml | – volume: 81 start-page: 687 year: 1995 end-page: 693 article-title: Identification of a nuclear receptor that is activated by farnesol metabolites publication-title: Cell – volume: 68 start-page: 230 year: 2018 end-page: 237 article-title: Preclinical models of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 11 start-page: 55 year: 2014 end-page: 67 article-title: Bile acid receptors as targets for drug development publication-title: Nat Rev Gastroenterol Hepatol – volume: 41 start-page: 1313 year: 2005 end-page: 1321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 48 start-page: 1632 year: 2008 end-page: 1643 article-title: Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response publication-title: Hepatology – volume: 148 start-page: 547 year: 2015 end-page: 555 article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States publication-title: Gastroenterology – volume: 4 start-page: 741 year: 2010 end-page: 748 article-title: Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non‐alcoholic fatty liver disease publication-title: Hepatol Int – volume: 123 start-page: 4579 year: 2013 end-page: 4594 article-title: A nonclassical vitamin D receptor pathway suppresses renal fibrosis publication-title: J Clin Invest – volume: 15 start-page: 249 year: 2016 end-page: 274 article-title: Non‐alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies publication-title: Nat Rev Drug Discov – volume: 78 start-page: 617 year: 2010 end-page: 630 article-title: Functional characterization of the semisynthetic bile acid derivative INT‐767, a dual farnesoid X receptor and TGR5 agonist publication-title: Mol Pharmacol – volume: 66 start-page: S431 year: 2017 end-page: S432 article-title: Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with biopsy‐confirmed NASH publication-title: J Hepatol – volume: 22 start-page: 1622 year: 2008 end-page: 1632 article-title: Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo publication-title: Mol Endocrinol – volume: 2 start-page: 217 year: 2005 end-page: 225 article-title: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis publication-title: Cell Metab – volume: 6 start-page: 1360 year: 2017 end-page: 1370 article-title: Superior reductions in hepatic steatosis and fibrosis with co‐administration of a glucagon‐like peptide‐1 receptor agonist and obeticholic acid in mice publication-title: Mol Metab – volume: 62 start-page: 2915 year: 2017 end-page: 2922 article-title: Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes publication-title: Dig Dis Sci – volume: 284 start-page: 1362 year: 1999 end-page: 1365 article-title: Identification of a nuclear receptor for bile acids publication-title: Science – volume: 302 start-page: G762 year: 2012 end-page: G772 article-title: Glucagon‐like peptide‐1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 50 start-page: 4265 year: 2007 end-page: 4268 article-title: Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23‐ and 6,23‐alkyl‐substituted bile acid derivatives as selective modulators for the G‐protein coupled receptor TGR5 publication-title: J Med Chem – volume: 385 start-page: 956 year: 2015 end-page: 965 article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial publication-title: Lancet – volume: 5 start-page: 17288 year: 2015 article-title: Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease publication-title: Sci Rep – volume: 64 start-page: A32 issue: Suppl. 1 year: 2016 article-title: First‐in‐human experience with LJN452, an orally available non‐bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects publication-title: Hepatology – volume: 13 start-page: 193 year: 2018 end-page: 205 article-title: Non‐alcoholic fatty liver disease (NAFLD) models in drug discovery publication-title: Expert Opin Drug Discov – volume: 305 start-page: G483 year: 2013 end-page: G495 article-title: Diet‐induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 127 start-page: 1497 year: 2004 end-page: 1512 article-title: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis publication-title: Gastroenterology – volume: 51 start-page: 380 year: 2009 end-page: 388 article-title: Farnesoid X receptor agonist WAY‐362450 attenuates liver inflammation and fibrosis in murine model of non‐alcoholic steatohepatitis publication-title: J Hepatol – volume: 30 start-page: 570 year: 2009 end-page: 580 article-title: Bile‐acid‐activated receptors: targeting TGR5 and farnesoid‐X‐receptor in lipid and glucose disorders publication-title: Trends Pharmacol Sci – volume: 67 start-page: 328 year: 2018 end-page: 357 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology – volume: 368 start-page: 17 year: 2013 end-page: 29 article-title: FXR signaling in the enterohepatic system publication-title: Mol Cell Endocrinol – volume: 284 start-page: 1365 year: 1999 end-page: 1368 article-title: Bile acids: natural ligands for an orphan nuclear receptor publication-title: Science – volume: 13 start-page: 643 year: 2015 end-page: 654 article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies publication-title: Clin Gastroenterol Hepatol – volume: 68 start-page: 551 year: 2005 end-page: 558 article-title: The methyl transferase PRMT1 functions as co‐activator of farnesoid X receptor (FXR)/9‐cis retinoid X receptor and regulates transcription of FXR responsive genes publication-title: Mol Pharmacol – volume: 45 start-page: 3569 year: 2002 end-page: 3572 article-title: 6alpha‐ethyl‐chenodeoxycholic acid (6‐ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity publication-title: J Med Chem – volume: 113 start-page: 1408 year: 2004 end-page: 1418 article-title: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP‐1c publication-title: J Clin Invest – volume: 145 start-page: 574 year: 2013 end-page: 582 article-title: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 51 start-page: 771 year: 2010 end-page: 784 article-title: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats publication-title: J Lipid Res – volume: 60 start-page: 9960 year: 2017 end-page: 9973 article-title: Discovery of tropifexor (LJN452), a highly potent non‐bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH) publication-title: J Med Chem – volume: 7 start-page: 562 year: 2012 end-page: 578 article-title: Differential gene and transcript expression analysis of RNA‐seq experiments with TopHat and Cufflinks publication-title: Nat Protoc – volume: 10 start-page: 686 year: 2013 end-page: 690 article-title: The global NAFLD epidemic publication-title: Nat Rev Gastroenterol Hepatol – volume: 103 start-page: 1006 year: 2006 end-page: 1011 article-title: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice publication-title: Proc Natl Acad Sci U S A – volume: 382 start-page: 1537 year: 2013 end-page: 1538 article-title: Liver disease in the UK: a Lancet Commission publication-title: Lancet – volume: 6 start-page: 517 year: 2000 end-page: 526 article-title: A regulatory cascade of the nuclear receptors FXR, SHP‐1, and LRH‐1 represses bile acid biosynthesis publication-title: Mol Cell – volume: 13 start-page: 213 year: 2012 end-page: 224 article-title: Transcriptional integration of metabolism by the nuclear sterol‐activated receptors LXR and FXR publication-title: Nat Rev Mol Cell Biol – volume: 226 start-page: 497 year: 1957 end-page: 509 article-title: A simple method for the isolation and purification of total lipides from animal tissues publication-title: J Biol Chem – volume: 6 start-page: 33453 year: 2016 article-title: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis publication-title: Sci Rep – volume: 22 start-page: 9039 year: 2016 end-page: 9043 article-title: Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease publication-title: World J Gastroenterol – volume: 175 start-page: 1289 year: 2018 end-page: 1306 article-title: Obesity drives STAT‐1‐dependent NASH and STAT‐3‐dependent HCC publication-title: Cell – volume: 24 start-page: 179 year: 2018 end-page: 194 article-title: Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet‐induced obese mouse models of biopsy‐confirmed nonalcoholic steatohepatitis publication-title: World J Gastroenterol – volume: 119 start-page: 1322 year: 2009 end-page: 1334 article-title: Consuming fructose‐sweetened, not glucose‐sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans publication-title: J Clin Invest – volume: 53 start-page: 1874 year: 2011 end-page: 1882 article-title: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality publication-title: Hepatology – volume: 54 start-page: 1326 year: 2013 end-page: 1334 article-title: Hepatic cholesterol crystals and crown‐like structures distinguish NASH from simple steatosis publication-title: J Lipid Res – volume: 305 start-page: G483 year: 2013 ident: hep41368-bib-0036-20240114 article-title: Diet‐induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00079.2013 – volume: 13 start-page: 643 year: 2015 ident: hep41368-bib-0046-20240114 article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.014 – volume: 62 start-page: 2915 year: 2017 ident: hep41368-bib-0006-20240114 article-title: Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes publication-title: Dig Dis Sci doi: 10.1007/s10620-017-4684-x – volume: 54 start-page: 1326 year: 2013 ident: hep41368-bib-0038-20240114 article-title: Hepatic cholesterol crystals and crown‐like structures distinguish NASH from simple steatosis publication-title: J Lipid Res doi: 10.1194/jlr.M034876 – volume: 22 start-page: 9039 year: 2016 ident: hep41368-bib-0039-20240114 article-title: Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i41.9039 – volume: 15 start-page: 249 year: 2016 ident: hep41368-bib-0001-20240114 article-title: Non‐alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2015.3 – volume: 51 start-page: 380 year: 2009 ident: hep41368-bib-0020-20240114 article-title: Farnesoid X receptor agonist WAY‐362450 attenuates liver inflammation and fibrosis in murine model of non‐alcoholic steatohepatitis publication-title: J Hepatol doi: 10.1016/j.jhep.2009.03.025 – volume: 10 start-page: 686 year: 2013 ident: hep41368-bib-0002-20240114 article-title: The global NAFLD epidemic publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.171 – volume: 368 start-page: 17 year: 2013 ident: hep41368-bib-0009-20240114 article-title: FXR signaling in the enterohepatic system publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2012.05.004 – volume: 53 start-page: 1874 year: 2011 ident: hep41368-bib-0004-20240114 article-title: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality publication-title: Hepatology doi: 10.1002/hep.24268 – volume: 6 start-page: 33453 year: 2016 ident: hep41368-bib-0021-20240114 article-title: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis publication-title: Sci Rep doi: 10.1038/srep33453 – volume: 302 start-page: G762 year: 2012 ident: hep41368-bib-0034-20240114 article-title: Glucagon‐like peptide‐1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00476.2011 – volume: 382 start-page: 1537 year: 2013 ident: hep41368-bib-0007-20240114 article-title: Liver disease in the UK: a Lancet Commission publication-title: Lancet doi: 10.1016/S0140-6736(13)62152-2 – volume: 51 start-page: 771 year: 2010 ident: hep41368-bib-0026-20240114 article-title: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats publication-title: J Lipid Res doi: 10.1194/jlr.M001602 – volume: 13 start-page: 213 year: 2012 ident: hep41368-bib-0008-20240114 article-title: Transcriptional integration of metabolism by the nuclear sterol‐activated receptors LXR and FXR publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3312 – volume: 64 start-page: A32 issue: Suppl. 1 year: 2016 ident: hep41368-bib-0040-20240114 article-title: First‐in‐human experience with LJN452, an orally available non‐bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects publication-title: Hepatology – volume: 24 start-page: 179 year: 2018 ident: hep41368-bib-0045-20240114 article-title: Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet‐induced obese mouse models of biopsy‐confirmed nonalcoholic steatohepatitis publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i2.179 – volume: 175 start-page: 1289 year: 2018 ident: hep41368-bib-0047-20240114 article-title: Obesity drives STAT‐1‐dependent NASH and STAT‐3‐dependent HCC publication-title: Cell doi: 10.1016/j.cell.2018.09.053 – volume: 30 start-page: 570 year: 2009 ident: hep41368-bib-0048-20240114 article-title: Bile‐acid‐activated receptors: targeting TGR5 and farnesoid‐X‐receptor in lipid and glucose disorders publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2009.08.001 – volume: 284 start-page: 1365 year: 1999 ident: hep41368-bib-0011-20240114 article-title: Bile acids: natural ligands for an orphan nuclear receptor publication-title: Science doi: 10.1126/science.284.5418.1365 – volume: 6 start-page: 517 year: 2000 ident: hep41368-bib-0013-20240114 article-title: A regulatory cascade of the nuclear receptors FXR, SHP‐1, and LRH‐1 represses bile acid biosynthesis publication-title: Mol Cell doi: 10.1016/S1097-2765(00)00051-4 – volume: 385 start-page: 956 year: 2015 ident: hep41368-bib-0028-20240114 article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61933-4 – volume: 127 start-page: 1497 year: 2004 ident: hep41368-bib-0022-20240114 article-title: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.08.001 – volume: 119 start-page: 1322 year: 2009 ident: hep41368-bib-0043-20240114 article-title: Consuming fructose‐sweetened, not glucose‐sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans publication-title: J Clin Invest doi: 10.1172/JCI37385 – volume: 2 start-page: 217 year: 2005 ident: hep41368-bib-0014-20240114 article-title: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis publication-title: Cell Metab doi: 10.1016/j.cmet.2005.09.001 – volume: 48 start-page: 1632 year: 2008 ident: hep41368-bib-0018-20240114 article-title: Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response publication-title: Hepatology doi: 10.1002/hep.22519 – volume: 68 start-page: 230 year: 2018 ident: hep41368-bib-0042-20240114 article-title: Preclinical models of non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2017.10.031 – volume: 4 start-page: 741 year: 2010 ident: hep41368-bib-0017-20240114 article-title: Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non‐alcoholic fatty liver disease publication-title: Hepatol Int doi: 10.1007/s12072-010-9202-6 – volume: 284 start-page: 1362 year: 1999 ident: hep41368-bib-0012-20240114 article-title: Identification of a nuclear receptor for bile acids publication-title: Science doi: 10.1126/science.284.5418.1362 – volume: 148 start-page: 547 year: 2015 ident: hep41368-bib-0005-20240114 article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.11.039 – volume: 50 start-page: 4265 year: 2007 ident: hep41368-bib-0029-20240114 article-title: Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23‐ and 6,23‐alkyl‐substituted bile acid derivatives as selective modulators for the G‐protein coupled receptor TGR5 publication-title: J Med Chem doi: 10.1021/jm070633p – volume: 113 start-page: 1408 year: 2004 ident: hep41368-bib-0023-20240114 article-title: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP‐1c publication-title: J Clin Invest doi: 10.1172/JCI21025 – volume: 78 start-page: 617 year: 2010 ident: hep41368-bib-0030-20240114 article-title: Functional characterization of the semisynthetic bile acid derivative INT‐767, a dual farnesoid X receptor and TGR5 agonist publication-title: Mol Pharmacol doi: 10.1124/mol.110.064501 – volume: 11 start-page: 55 year: 2014 ident: hep41368-bib-0015-20240114 article-title: Bile acid receptors as targets for drug development publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.151 – volume: 6 start-page: 1360 year: 2017 ident: hep41368-bib-0037-20240114 article-title: Superior reductions in hepatic steatosis and fibrosis with co‐administration of a glucagon‐like peptide‐1 receptor agonist and obeticholic acid in mice publication-title: Mol Metab doi: 10.1016/j.molmet.2017.09.001 – volume: 13 start-page: 193 year: 2018 ident: hep41368-bib-0041-20240114 article-title: Non‐alcoholic fatty liver disease (NAFLD) models in drug discovery publication-title: Expert Opin Drug Discov doi: 10.1080/17460441.2018.1410135 – volume: 66 start-page: S431 year: 2017 ident: hep41368-bib-0044-20240114 article-title: Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with biopsy‐confirmed NASH publication-title: J Hepatol doi: 10.1016/S0168-8278(17)31230-8 – volume: 145 start-page: 574 year: 2013 ident: hep41368-bib-0027-20240114 article-title: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.05.042 – volume: 81 start-page: 687 year: 1995 ident: hep41368-bib-0010-20240114 article-title: Identification of a nuclear receptor that is activated by farnesol metabolites publication-title: Cell doi: 10.1016/0092-8674(95)90530-8 – volume: 5 start-page: 17288 year: 2015 ident: hep41368-bib-0024-20240114 article-title: Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease publication-title: Sci Rep doi: 10.1038/srep17288 – volume: 226 start-page: 497 year: 1957 ident: hep41368-bib-0033-20240114 article-title: A simple method for the isolation and purification of total lipides from animal tissues publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)64849-5 – volume: 7 start-page: 562 year: 2012 ident: hep41368-bib-0035-20240114 article-title: Differential gene and transcript expression analysis of RNA‐seq experiments with TopHat and Cufflinks publication-title: Nat Protoc doi: 10.1038/nprot.2012.016 – volume: 68 start-page: 551 year: 2005 ident: hep41368-bib-0050-20240114 article-title: The methyl transferase PRMT1 functions as co‐activator of farnesoid X receptor (FXR)/9‐cis retinoid X receptor and regulates transcription of FXR responsive genes publication-title: Mol Pharmacol doi: 10.1124/mol.105.012104 – volume: 123 start-page: 4579 year: 2013 ident: hep41368-bib-0049-20240114 article-title: A nonclassical vitamin D receptor pathway suppresses renal fibrosis publication-title: J Clin Invest doi: 10.1172/JCI67804 – volume: 103 start-page: 1006 year: 2006 ident: hep41368-bib-0025-20240114 article-title: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0506982103 – volume: 22 start-page: 1622 year: 2008 ident: hep41368-bib-0019-20240114 article-title: Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo publication-title: Mol Endocrinol doi: 10.1210/me.2007-0527 – volume: 67 start-page: 328 year: 2018 ident: hep41368-bib-0003-20240114 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29367 – volume: 60 start-page: 9960 year: 2017 ident: hep41368-bib-0031-20240114 article-title: Discovery of tropifexor (LJN452), a highly potent non‐bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH) publication-title: J Med Chem doi: 10.1021/acs.jmedchem.7b00907 – volume: 45 start-page: 3569 year: 2002 ident: hep41368-bib-0016-20240114 article-title: 6alpha‐ethyl‐chenodeoxycholic acid (6‐ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity publication-title: J Med Chem doi: 10.1021/jm025529g – volume: 41 start-page: 1313 year: 2005 ident: hep41368-bib-0032-20240114 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20701 |
SSID | ssj0001921190 |
Score | 2.433738 |
Snippet | Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile... |
SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1085 |
SubjectTerms | Bile Cytochrome Experiments Fibroblasts Gene expression Growth factors Inflammation Laboratory animals Ligands Lipids Liver diseases Metabolism Metabolites Mortality Original Oxidative stress Polyethylene glycol Polymerase chain reaction Transplants & implants Variance analysis |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLXQLBAbxJvAMDKIBZtqEr8SL8uoVUEqGqEZMTvLTmyaWcRV05G6ZMmSb5wvmWs7rVoBYsOmSvPSzX3I5yg35yL0XldMGkGhvinXI-Ys1Jx2btQwUthCCybibMD5FzG7ZJ-v-NXeqK_QE5bkgZPjTh2sZxY4gw5cpGC6IoZSSnJXO2AWPH26l5M9MnWdcEsBS91WSignpwu7ZKGnqzpYgKJO_5_A5e89kvvYNS4-00fo4YAa8ThZ-xjds90TdH8-vBd_in5erPyydXbjV7c_fs3j-A3b4LFZ-e_R9dg7HFp31x4sDBnS9lh3DZ4CW_Y9_PnU422k4MJv7XqBARricWiG3LRNlAfHQaMaTzZD72yHz9PAb9x2-KsPX_z2z9DldHJxNhsNMxZGNaeBQBYl-KkhubCNLnhpSgE7mppQqUUuiQEEHjBirnMB3ErLktTE1MwZblwtKX2Ojjrf2ZcIE8apK2wdFNVZpSvZlFYAneMO7sWpzNC7rePVMklpqCSaTFSIjgrRydDHEJLdCUH9Ou6AnFBDTqh_5USGjrcBVUNJ9gpwZkm5hN8Mvd0dhmIKb0h0Z_1NPEdGSTiw40WK_84SWtAK6B_cvDzIjANTD4907SIKdgtRghPzDH2IOfT3p1ezyTkLG6_-hxteowcA72RqVzxGR-vVjX0DEGptTmK13AFpdhiT priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxHsLCzKIA5doE9ux4xMqqFVBKlqhXdFb5CT2Npe4JF2pR44c-Y38EmacpEvF4xIlcR62Zyb-xp58Q8hrkwldSA72zVMTCWfB5oxzUSVYYhMjhQy5AZef5OJCfFylq2HCrRvCKsdvYvhQV77EOfJTgAmKpxq2bzdfI8wahaurQwqNm-RWwmAoB31WK3U9x6KRvyweCYVidrq2G4GRXdnBMBTY-v8GMf-MlPwdwYYhaH6P3B2wI532wr5PbtjmAbm9HFbHH5Lv563f1M7ufPvz249lSMJhKzotWn8ZBEC9oxjAu_VQQ9STuqOmqegcfGbfwcGHjo7yghu_1Ns1BYBIpxgSuaurQBJOkamaznZDBG1Dz_q037Ru6GeP__12j8jFfHb-fhENmRaiMuXoRiYK-qlisbSVSVJVKAknqpJxbWSsWQE4HJFibGIJHpbRipWsKIUr0sKVmvPH5KjxjT0mlImUu8SWyKsuMpPpSlkJTl3q4Fkp1xPyauz4fNMTauQ9dTLLUTo5SmdC3qFI9hcgB3Y44dvLfDCp3AHSseBNGvRSE2EyVnDOWexKB29O4U0no0DzwTC7_FqNJuTlvhhMCtdJTGP9VbhGB2I4qMeTXv77mvCEZ-AEwsPVgWYcVPWwpKnXgbZbSgWdGE_Im6BD_259vpidCdx5-v8WPCN3AL7pPhzxhBxt2yv7HCDStngR7OAXVVoRpQ priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELaWRUJcEO_tsiCDOHCJNrEdJxangloVpKIK7YreIjuxt7kkVdKVeuS4R34jv4QZ57FUgMQlShwndjwe5xt7_A0hb3UqlJEc9JvHOhDOgs5p54JCsMhGWgrpYwMuv8jFpfi8jtdH5P2wF6bjhxgn3FAz_HiNCq5Ne35LGrqxW4FOWukdchdgjcTwBUysbidYFJKX4RwLgwE4AENoPTALhex8fPrgf-Rp-_-GNf90mfwdyvp_0fwhedCDSDrtpP6IHNnqMbm37JfJn5Cbi6bels7u6-bn9x9LH43DFnRqmvrKS4LWjqIn766GGmKHKVuqq4LOoUXqFi4-tXQQHDz4rdxtKCBFOkXfyH1ZeLZwipTVdLbvXWkruurif9Oyol9r3ADcPiWX89nFx0XQh1wI8pijPRkl0GYFC6UtdBQnJpGQUOSMKy1DxQwAcoSMoQ4lmFpaJSxnJhfOxMblivNn5LiqK3tCKBMxd5HNkWBdpDpVRWIlWHexg3fFXE3Im6Hhs23HrJF1HMosQ-lkKJ0J-YAiGTMgGbZPqJurrNetzAHksWBWajRXI6FTZjjnLHS5g5JjKOlsEGjWa2ibAexMeKzgOCGvx9ugW7hgoitbX_s8yjPEQT2ed_Ifa8IjnoI1CC9PDnrGQVUP71TlxvN3S5lAI4YT8s73oX9_fbaYrQSenP5_1hfkPmA61fkonpHjXXNtXwJu2plXXj9-AZgfE6o priority: 102 providerName: Wiley-Blackwell |
Title | Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep4.1368 https://www.ncbi.nlm.nih.gov/pubmed/31388629 https://www.proquest.com/docview/2267359267 https://search.proquest.com/docview/2269393588 https://pubmed.ncbi.nlm.nih.gov/PMC6672390 https://doaj.org/article/f910e104a218414a82b33320fcf44859 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF41RUJcUHnWtEQL4sAljb3P-JhWiQJSKqtqIOJire3dxojakZ1KOXLkyG_klzC7tqNGwIWLk_iRnezMaL-JP3-D0Ds1YmEiKOQ35WrAjIacU8YMMkYCHSjBhOsNOL8UswX7uOTLA8S7Z2EcaT9N8rPi2-1Zka8ct3J9mw47ntgwml8IIQnU6sMe6sHye69E_9pAlgBWuU5FyCfDlV4zS-eyvfloQEcA4sO9Zcip9f8NYv7JlLyPYN0SND1Cj1vsiMeNjU_QgS6eoofz9u74M_TjuirXudHbsvr1_efcNeHQGR4nVXnjHIBLgy2Bd1OCsTZO8hqrIsNTqJnLGj58qHHnL7jwc75ZYQCIeGwpkds8cyLh2CpV48m2ZdAWOGrafuO8wFelfe63fo4W08n1xWzQdloYpJzaMjKQMGUZ8YXOVMBlIgXsyFKYZSX8kCSAwy1S9JUvoMJSoSQpSVJmEp6YNKT0BTosykIfI0wYpybQqdVVZyM1CjOpBRR13MB3cRp66G038fG6EdSIG-lkEltHxdZRHjq3LtmdYDWw3Y6yuonbSIgNIB0N1aSyVWrA1IgklFLim9TAyBxGOu0cGreJWceANiXlIWw99GZ3GFLK3idRhS7v3DmhE4YDO142_t9Z0sWPh-ReZOyZun8EotjJdrdR66H3Lob-_evj2SRi9s2r_x7kBD0CZBc2TMVTdLip7vRrQE-bpI96hEWwlUvZRw_GnxZfFvB6PrmMrvruH4m-y6ffzzIgqg |
link.rule.ids | 230,314,727,780,784,864,885,2102,11562,12056,21388,27924,27925,31719,31720,33744,33745,43310,43805,46052,46476,50814,50923,53791,53793,73745,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELagKwEXxHMpLGAQBy7RJn4lPqEuatWFbVWtumJvkZPY21ziknSlHjly5DfySxg7SZeKxyXK05l4PPY39uQbhN6phMlMULBvylXAjAabU8YEBSORjpRgwucGnM3F9IJ9uuSX3YRb04VV9n2i76gLm7s58mOACTHlErYf1l8DlzXKra52KTRuowPHnM4H6OBkPF-c38yySMdgFvaUQiE5Xuk1c7Fdyd5A5Pn6_wYy_4yV_B3D-kFo8gDd79AjHrXqfohu6eoRujPr1scfo-_L2q5Lo7e2_vntx8yn4dAFHmW1vfIqwNZgF8K7sSChayllg1VV4Al4zbaBg9MG9xqDB7-UmxUGiIhHLihyWxaeJhw7rmo83nYxtBVetIm_cVnhc-v-_G2eoIvJePlxGnS5FoKcU-dIRjHUU0FCoQsV8TiLBZwockKlEqEkGSBxhxVDFQrwsZSMSU6ynJmMZyaXlD5Fg8pW-hnChHFqIp07ZnWWqEQWsRbg1nEDZXEqh-htX_HpuqXUSFvyZJI67aROO0N04lSyu8GxYPsTtr5KO6NKDWAdDf6kcn5qxFRCMkopCU1u4M0c3nTUKzTtTLNJbxrSEL3ZXQajcislqtL22t8jPTUcyHHY6n8nCY1oAm4gFB7vtYw9UfevVOXKE3cLEUMlhkP03rehf399Oh0vmNt5_v8veI3uTpezs_TsdP75BboHYE62wYlHaLCpr_VLAEyb7FVnFb8A-q0V-w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LjtMwFLWgI43YIN5TGMAgFmyiJrbjxCvUgVYdoFU1mhGzi5zEnmYTl6QjdcmSJd_Il3DtOB0qHpso7zi-vva58cm5CL2RKRM5p-DfNJYB0wp8TmodlIxEKpKccZcbcL7gswv28TK-9Pyn1tMq-z7RddSlKew38hHAhITGApYj7WkRyw_Td-uvgc0gZWdafTqN2-gARsWQDNDByWSxPLv54iKsmlnYywuFZLRSa2Z5XuneoOS0-_8GOP_kTf6OZ92ANL2H7nokiced6e-jW6p-gA7nfq78Ifp-3ph1pdXWND-__Zi7lByqxOO8MVfOHNhobOm8GwMltK2marGsSzyFCNq0sHHa4t56cOGXarPCABfx2BIkt1XpJMOx1a3Gk63n09Z42SUBx1WNz4z9C7h9hC6mk_P3s8DnXQiKmNqgMkqgnkoSclXKKE7yhMOOsiBUSB4KkgMqt7gxlCGHeEuKhBQkL5jO41wXgtLHaFCbWh0hTFhMdaQKq7LOUpmKMlEcQrxYw71iKobodV_x2bqT18g6IWWSWetk1jpDdGJNsjvBKmK7Haa5yryDZRpwj4LYUtqYNWIyJTmllIS60PDkGJ503Bs0827aZjeNaohe7Q6Dg9lZE1krc-3OEU4mDsrxpLP_riQ0oimEhHDzZK9l7BV1_0hdrZyIN-cJVGI4RG9dG_r322ezyZLZlaf_f4OX6BAcIvt8uvj0DN0BXCc6nuIxGmyaa_UcsNMmf-Gd4hff6hoo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tropifexor-Mediated+Abrogation+of+Steatohepatitis+and+Fibrosis+Is+Associated+With+the+Antioxidative+Gene+Expression+Profile+in+Rodents&rft.jtitle=Hepatology+communications&rft.au=Hernandez%2C+Eloy+D&rft.au=Zheng%2C+Lianxing&rft.au=Kim%2C+Young&rft.au=Fang%2C+Bin&rft.date=2019-08-01&rft.eissn=2471-254X&rft.volume=3&rft.issue=8&rft.spage=1085&rft_id=info:doi/10.1002%2Fhep4.1368&rft_id=info%3Apmid%2F31388629&rft.externalDocID=31388629 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2471-254X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2471-254X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2471-254X&client=summon |